Dublin, Nov. 10, 2015 (GLOBE NEWSWIRE) -- Research and Markets ( http://www.researchandmarkets.com/research/3z...ontyrosine ) has announced the addition of the "Non-Tyrosine Kinase Inhibitors in Oncology, 2015 - 2025" report to their offering. The Non-Tyrosine Kinase Inhibitors in Oncology, 2015-2025 report provides a comprehensive analysis of the current market landscape and the future outlook of kinase inhibitors not specifically targeting tyrosine kinases. These include kinase inhibitors with activity against serine/threonine kinases, dual specificity kinases or both tyrosine and serine/threonine kinases being developed for oncological indications. Targeted therapy, specifically small molecule protein kinase inhibitors, has emerged as the new generation of cancer treatment that specifically targets only cancer cells.
Although the market of protein kinase inhibitors is dominated by tyrosine kinase inhibitors, non-tyrosine kinase inhibitors (serine/threonine kinase inhibitors, dual specificity kinase inhibitors and drugs that inhibit both tyrosine and serine/threonine kinases) have gained a significant momentum in the last few years.
There are total seven marketed non-tyrosine kinase inhibitors approved so far. Nexavar, the first drug of this type, received approval in 2005. Subsequently, Torisel (2007), Afinitor (2009), Zelboraf (2011), Tafinlar (2013), Mekinist (2013) and Ibrance (2015) were approved. The pipeline is rich and holds a significant potential for future.
In fact, non-tyrosine kinase inhibitors have gradually gained attention in the last few years. Amongst the marketed drugs, Nexavar and Afinitor have already achieved blockbuster status. With several new drugs under development, companies are also evaluating combination therapies of marketed drugs for the approved or additional oncological indications. Apart from the bigger pharmaceutical companies such as Roche/Genentech, Eli Lilly, Novartis, Pfizer, AstraZeneca, several smaller/ start-up companies have shown their participation in this area. As the industry gains momentum, many companies have already benefitted by adopting the strategy of discovering the compounds and then out-licensing to bigger companies. Most of the non-tyrosine kinase inhibitors identified during our research target mTOR, CDK, RAF and MEK kinases. In addition, there are several novel non-tyrosine kinase inhibitors under development that target other serine/threonine and dual specificity kinases (e.g. PLK1, ERK, PIM, Chk kinases). The report covers various aspects such as key players, marketed non-tyrosine kinase inhibitors, products in clinical / pre-clinical research, associated patents, likely future developments and upcoming opportunities for a variety of stakeholders.With the seven marketed drugs and several in late stage of development, the market is expected to grow at a healthy rate in the coming few years. The report elaborates and provides detailed sales forecasts of many promising drugs for the period 2015 - 2025. Owing to the relatively niche nature of the market, we have provided three market forecast scenarios to add robustness to our model. The conservative, base and optimistic scenarios represent three different tracks of industry evolution. Example Highlights: - Approximately 140 non-tyrosine kinase inhibitors are in different stages of development. In addition to the seven marketed drugs, nine are expected to be commercialized by 2017/2018. 70% of the pipeline drugs are in early stages of development. Most of the drugs being developed are serine/threonine kinase inhibitors. - In addition to the common drug classes (mTOR / CDK / RAF/ MEK inhibitors), many novel non tyrosine kinase inhibitors are also being developed. Overall, 35% of the pipeline drugs are based on these novel inhibitors; examples include AKT/ERK/PIM/PLK/Chk/Aurora kinase inhibitors. - Combination therapies are expected to act as the main driver of the market. Several drugs (both marketed and pipeline) are being evaluated as combination therapies. In fact, earlier this year, Ibrancereceived initial approval as a combination therapy. Another drug, cobimetinib, has been filed for initial NDA as combination therapy. - Currently, mTOR inhibitors (53%) and RAF/MEK inhibitors (46%) are the main contributors to the market.With the launch of additional drugs, CDK inhibitors are likely to gain significant ground; by 2025, we forecast CDK inhibitors to capture 33% of the market. - Apart from the well-established names, several small and new companies have gained foothold in the market. These include Onconova Therapeutics, Eternity Biosciences, Nerviano Medical Sciences, Cyclacel Pharmaceuticals, G1 Therapeutics, Tragara Pharmaceuticals, SignalRx, Jasco Pharmaceuticals, Tolero Pharma, Hanmi Pharma, CASI Pharma, Tekmira, Ability Pharma, Piqur, Verastem, Flexus, Erimos Pharma, Agennix, Taiho Pharma, OncoTherapy Science, ArQule, Advenchen Laboratories, Bionovo, Inflection Biosciences, Xcovery, Selvita Syros Pharma, Enzo Life Sciences Asana Biosciences, Allomek Therapeutics, ÆternaZentaris and Aptose Biosciences. - In addition to Nexavar and Afinitor, there are other drugs with the potential to achieve a blockbuster status; combined with a favourable regulatory regime, the overall opportunity could be significantly higher. Key Topics Covered: 1. Preface 2. Executive Summary 3. Cancer Therapeutics and Targeted Cancer Therapy 4. Non-Tyrosine Kinase Inhibitors: Current Market Landscape 5. mTOR Inhibitors: Key Molecules and Future Outlook 6. Cdk Inhibitors: Key Molecules and Future Outlook 7. RAF / MEK Inhibitors: Key Molecules and Future Outlook 8. Novel Non-Tyrosine Kinase Inhibitors: Key Molecules and Future Outlook 9. Company Profiles 10. Interview Transcripts 11. Conclusion 12. Appendix 1: Tabulated Data 13. Appendix 2: List of Companies and Organizations Companies Mentioned - Ability Pharma - Accord Healthcare - Advenchen Laboratories - ÆternaZentaris - Agennix - Allomek Therapeutics - Altana - Ambit - Amgen - Aptose Biosciences (formerly named Lorus Therapeutics) - Ariad Pharmaceuticals - ArQule - Array BioPharma - Asana Biosciences - ASLAN Pharmaceutical - Astex Pharmaceuticals - AstraZeneca - Barclays - Baxter International - Bayer - BeiGene - Biocon - Biogen - Bionovo - Boehringer Ingelheim - Bristol Myers Squibb - Carna Biosciences - CASI Pharmaceuticals - Celgene - ChemDiv. - Chugai - Chugai Pharmaceuticals - Cipla - Crown Biosciences - Cyclacel Pharmaceuticals - Daiichi Sankyo - Deciphera Pharmaceuticals - Eli Lilly - EMD Serono - Enzo Life Sciences - Erimos Pharma - Eternity Bioscience - Exelixis - Flexus - G1 Therapeutics - Genentech - Genzyme - GSK - GVK Biosciences - Hangzhou Tigermed Consulting - Hanmi Pharmaceutical - Ignyta - Incyte - Inflection Biosciences - J&J - Janssen - Jasco Pharmaceuticals - Jiangsu Heingrui Medicine - Loxo Oncology - McLaren - Medinol - MedPacto - Merck - Millennium Pharmaceuticals - Natco Pharma - NerPharMa DS - Nerviano Medical Sciences - Novartis - Onconova Therapeutics - OncoTherapy Science - Oncothyreon - OncoVeture - Onyx - OSI Pharmaceutical - Otsuka Pharmaceuticals - Pfizer - Pharmacyclics - Piqur - Piramal Life Sciences - Plexxikon - Ranbaxy - RaQualia Pharma - Rigel Pharmaceuticals - Roche Group - Sandoz - Sanofi - Selvita - Sentinel Oncology - Servier - SignalRx Pharmaceuticals - Sunesis Pharmaceuticals - Suzhou Zelgen Biopharmaceuticals - Symbio Pharmaceutical - Syros Pharma - Taiho Pharmaceutical - Tekmira - Teva - Tiziana - Tolero Pharmaceuticals - Tragara Pharmaceuticals - Traslational Cancer Drugs Pharma - UCB - Verastem - Wilex - Wyeth Pharmaceuticals - Xcovery - Youai Co. For more information visit http://www.researchandmarkets.com/research/3z...ontyrosine
CONTACT: Research and Markets Laura Wood, Senior Manager press@researchandmarkets.com For E.S.T Office Hours Call 1-917-300-0470 For U.S./CAN Toll Free Call 1-800-526-8630 For GMT Office Hours Call +353-1-416-8900 U.S. Fax: 646-607-1907 Fax (outside U.S.): +353-1-481-1716 Sector: Oncology, Enzymes
